Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer
JAMA · 13.06.2023 · 329 (22) · 1924
DOI: 10.1001/jama.2023.7843 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA, erschienen am 13.06.2023. Verfasst von Deborah Schrag und 16 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Hemorrhage, Heparin, Low-Molecular-Weight, Neoplasms, Venous Thromboembolism. Die Arbeit wurde bisher 144-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance In patients with cancer who have venous thromboembolism (VTE) events, long-term anticoagulation with low-molecular-weight heparin (LMWH) is recommended to prevent recurrent VTE. The effectiveness of a direct oral anticoagulant (DOAC) compared with LMWH for preventing recurrent VTE in patients with cancer is uncertain.
Objective
To evaluate DOACs, compared with LMWH, for preventing recurrent VTE and for rates of bleeding in patients with cancer following an initial VTE event. Design, Setting, and Participants Unblinded, comparative effectiveness, noninferiority randomized clinical trial conducted at 67 oncology practices in the US that enrolled 671 patients with cancer (any invasive solid tumor, lymphoma, multiple myeloma, or chronic lymphocytic leukemia) who had a new clinical or radiological diagnosis of VTE. Enrollment occurred from December 2016 to April 2020. Final follow-up was in November 2020.
Intervention
Participants were randomized in a 1:1 ratio to either a DOAC (n = 335) or LMWH (n = 336) and were followed up for 6 months or until death. Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses. Main Outcomes and Measures The primary outcome was the recurrent VTE rate at 6 months. Noninferiority of anticoagulation with a DOAC vs LMWH was defined by the upper limit of the 1-sided 95% CI for the difference of a DOAC relative to LMWH of less than 3% in the randomized cohort that received at least 1 dose of assigned treatment. The 6 prespecified secondary outcomes included major bleeding, which was assessed using a 2.5% noninferiority margin.
Results
Between December 2016 and April 2020, 671 participants were randomized and 638 (95%) completed the trial (median age, 64 years; 353 women [55%]). Among those randomized to a DOAC, 330 received at least 1 dose. Among those randomized to LMWH, 308 received at least 1 dose. Rates of recurrent VTE were 6.1% in the DOAC group and 8.8% in the LMWH group (difference, −2.7%; 1-sided 95% CI, −100% to 0.7%) consistent with the prespecified noninferiority criterion. Of 6 prespecified secondary outcomes, none were statistically significant. Major bleeding occurred in 5.2% of participants in the DOAC group and 5.6% in the LMWH group (difference, −0.4%; 1-sided 95% CI, –100% to 2.5%) and did not meet the noninferiority criterion. Severe adverse events occurred in 33.8% of participants in the DOAC group and 35.1% in the LMWH group. The most common serious adverse events were anemia and death. Conclusions and Relevance Among adults with cancer and VTE, DOACs were noninferior to LMWH for preventing recurrent VTE over 6-month follow-up. These findings support use of a DOAC to prevent recurrent VTE in patients with cancer. Trial Registration ClinicalTrials.gov Identifier: NCT02744092
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Dana-Farber/Brigham and Women's Cancer Center and Harvard Medical School, Boston, Massachusetts.
- Memorial Sloan Kettering Cancer Center, New York, New York.
- Massachusetts General Hospital and Harvard Medical School, Boston.
- University of Texas Southwestern, Dallas.
- Washington University School of Medicine, St Louis, Missouri.
- University of Kentucky School of Medicine, Lexington.
Förderung
- NCI NIH HHS
Zitieren
APA
Schrag, D., Uno, H., Rosovsky, R., Rutherford, C., Sanfilippo, K., Villano, J. L., Drescher, M., Jayaram, N., Holmes, C., Feldman, L., Zattra, O., Farrar-Muir, H., Cronin, C., Basch, E., Weiss, A., Connors, J. M., & CANVAS Investigators (2023). Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer. JAMA, 329(22), 1924. https://doi.org/10.1001/jama.2023.7843
Vancouver
Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer. JAMA. 2023;329(22):1924. doi:10.1001/jama.2023.7843
BibTeX
@article{Schrag2023,
author = {Schrag, Deborah and Uno, Hajime and Rosovsky, Rachel and Rutherford, Cynthia and Sanfilippo, Kristen and Villano, John L and Drescher, Monic and Jayaram, Nagesh and Holmes, Chris and Feldman, Lawrence and Zattra, Ottavia and Farrar-Muir, Haley and Cronin, Christine and Basch, Ethan and Weiss, Anna and Connors, Jean M and CANVAS Investigators, CANVAS Investigators},
title = {Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer},
journal = {JAMA},
year = {2023},
volume = {329},
number = {22},
pages = {1924},
doi = {10.1001/jama.2023.7843}
}
EUVIMED